Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Orthocell Ltd ( (AU:OCC) ) has shared an announcement.
Orthocell Ltd has rapidly expanded its US distribution network for its nerve repair product, Remplir™, appointing 12 distributors across 21 states, surpassing its initial target. This strategic expansion, following FDA clearance, is expected to significantly boost the company’s revenue and market penetration in the US$1.6 billion nerve repair market, leveraging experienced distributors and internal sales teams to drive growth.
More about Orthocell Ltd
Orthocell Ltd is a regenerative medicine company specializing in products for nerve repair. Its flagship product, Remplir™, is a collagen wrap used in nerve repair surgery to enhance outcomes in the repair and regeneration of damaged nerves. The company is targeting a large global nerve repair market, with regulatory approvals in several countries and applications pending in others.
Average Trading Volume: 1,615,638
Technical Sentiment Signal: Buy
Current Market Cap: A$375.1M
Learn more about OCC stock on TipRanks’ Stock Analysis page.